Summit Therapeutics Inc.

0 products tracked · names used in filings: Summit Therapeutics Inc.

Upcoming milestones

Sat 14 Nov 2026🇺🇸 PDUFA datecompany-announcedtoday

ivonescimab: PDUFA target action date (EGFR-mutated locally advanced or metastatic non-squamous NSCLC after prior EGFR TKI therapy (with chemotherapy))

Summit Therapeutics Inc. (SMMT); ivonescimab; BLA; status: set; "The FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026."; filed 2026-11-04 · source

Recent milestones

No recent milestones.

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.